8-K: SS Innovations Reports Record Q1 2025 Revenue Driven by SSi Mantra 3 Sales

SS Innovations International, Inc. announced a 40.8% increase in revenue to $5.1 million for the first quarter of 2025, driven by higher sales of the SSi Mantra 3 surgical robotic system.

Summary

• SS Innovations International, Inc. reported unaudited financial results for the three months ended March 31, 2025.
• Revenue increased by 40.8% to $5.1 million, compared to $3.6 million in the first quarter of 2024.
• Gross margin expanded by 121 basis points to 21.23% from 20.02% in the same period last year.
• Gross profit rose by 49.3% to $1.1 million from $0.7 million in the first quarter of 2024.
• The net loss was $5.7 million, or $(0.03) per diluted share, compared to a net loss of $9.8 million, or $(0.06) per diluted share, in the first quarter of 2024.
• SSi Mantra surgical robotic system installations totaled 15, a 66.7% increase from 9 installations in the first quarter of 2024.
• As of March 31, 2025, the company had $15.9 million in cash and cash equivalents, excluding restricted cash.
• The cumulative installed base of SSi Mantra systems reached 78, and cumulative surgeries totaled 3,568.
• The company plans to submit a De Novo application to the FDA for SSi Mantra by the end of July 2025.
• The company is also pursuing a European Union CE Mark decision as soon as late 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved gross margins, and a reduced net loss. The uplisting to Nasdaq and plans for regulatory approvals further contribute to a favorable sentiment.

Positives

• Revenue increased significantly by 40.8% to $5.1 million in Q1 2025.
• Gross margin expanded to 21.23%, indicating improved profitability.
• Net loss decreased from $9.8 million to $5.7 million, showing progress towards profitability.
• SSi Mantra installations increased by 66.7%, demonstrating growing market adoption.
• The company uplisted to Nasdaq, enhancing its visibility and access to capital.
• The company is actively pursuing regulatory approvals in the US and Europe, expanding its market reach.
• Instrument sales increased 302.7% to $477,208.
• Warranty sales increased 1,202.3% to $122,504.

Negatives

• The company still reported a net loss of $5.7 million for the quarter.
• Operating expenses remain high at $7.0 million.
• The company is reliant on regulatory approvals for future growth.

Risks

• The company's future financial performance depends on obtaining regulatory approvals in the US and Europe.
• The company faces competition in the surgical robotics market.
• The company's growth strategy relies on expanding its presence beyond the seven countries where its SSi Mantra surgical robotic system has been cleared to market.
• The company's actual results could differ materially from those presented in its forward-looking statements due to known and unknown risks, uncertainties and other factors.

Future Outlook

SS Innovations is focused on expanding its global presence, pursuing regulatory approvals in the European Union and United States, and continuing its robust organic growth.

Management Comments

• Dr. Sudhir Srivastava, Chairman and CEO, stated that the company achieved record quarterly revenue driven by higher unit sales of the SSi Mantra 3 surgical robotic system.
• Dr. Srivastava mentioned that the gross margin improved due to a reduction in raw material prices.
• Dr. Srivastava noted that the company is well positioned for continued robust organic growth during the remainder of the year.
• Dr. Srivastava stated that the uplisting to Nasdaq symbolizes a new chapter of global expansion for the company.
• Dr. Srivastava expressed the vision to decentralize and democratize robotic surgery by deploying cost-effective SSi Mantra 3 devices globally.

Industry Context

The announcement reflects the growing demand for surgical robotic systems and the increasing adoption of robotic surgery in healthcare facilities globally, particularly in emerging markets like India. SS Innovations is positioning itself as a cost-effective alternative to established players in the surgical robotics market.

Comparison to Industry Standards

• Intuitive Surgical, a leader in the surgical robotics market, reported $1.89 billion in revenue for Q1 2024, showcasing the scale of the established players.
• Stryker, another major player, has a diverse portfolio including robotics, but their specific robotics revenue is not always broken out.
• Medtronic also competes in the surgical robotics space, with their Hugo RAS system, aiming to challenge Intuitive Surgical's dominance.
• SS Innovations' focus on affordability and accessibility differentiates it from these competitors, targeting a different segment of the market.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and improved financial performance.
• Employees may see increased job security and growth opportunities.
• Customers (healthcare facilities) will have access to more affordable surgical robotic systems.
• Patients will benefit from increased access to robotic surgery.

Next Steps

• Submit a De Novo application to the FDA for SSi Mantra by the end of July 2025.
• Continue along the pathway towards a European Union CE Mark decision as soon as late 2025.
• Expand the global presence of its surgical robotic solutions.

Key Dates

Keywords

SS Innovations, SSi Mantra, surgical robotics, robotic surgery, financial results, revenue, gross margin, net loss, FDA, CE Mark, installations, telesurgery